drugset
drugset / Trial / NCT03864601

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

NCT03864601 ↗

Phase 1 Completed 6 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to investigate the absorption, the metabolic pathways, the route and rate of elimination, and total recovery of 14C-JNJ-56136379 and/or total drug derived radioactivity in healthy male adult participants after administration of a single oral dose of 14C-JNJ-56136379.

Timeline

Start
2019-04-09
Primary completion
2019-06-14
Completion
2019-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject bersacapavir Other / unclassified 25 mg Oral

Indications

No indication recorded.